Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 276
Filter
1.
Nurs Res ; 50(6): 374-8, 2001.
Article in English | MEDLINE | ID: mdl-11725940

ABSTRACT

BACKGROUND: Effective interventions to increase physical activity levels are critical in a nation where inactivity is a national public health problem. OBJECTIVE: This pilot study examined whether a minimal intervention (daily records of physical activity) increased activity levels in a community sample of working women. METHODS: In a longitudinal, pretest-posttest design, 49 working women were randomly assigned at the work site level to the control (n = 25) or intervention group (n = 24). At pretest and posttest, subjects completed self-report questionnaires that measured psychological, social-environmental, physical activity, and demographic variables. Subjects in the intervention group kept daily records of their physical activities during the 12-week study, while those in the control group kept no records. In order to compare activity in the two groups, all subjects wore pedometers daily that recorded number of steps. RESULTS: There was a significant difference between groups in the pedometer values (mean number of daily steps) at the end of the study period (mean difference +/- SE 2147 +/- 636, p = .022) (2000 steps = approximately 1 mile). Multiple regression analysis showed that only the intervention (p = .003) was a significant predictor of the pedometer values. Hierarchical data analysis was used to account for the intra-class correlation of 0.48 within work site. CONCLUSION: Results from this sample of 49 women indicated that mean activity was greater in the intervention group compared to the control group. Recording daily activity is a cost-effective and acceptable intervention that may increase activity levels in women. However, more research is recommended to study the dual role of activity records as a data collection method as well as a potential intervention to increase physical activity.


Subject(s)
Exercise , Health Promotion/methods , Medical Records , Women, Working , Adult , Analysis of Variance , Female , Humans , Middle Aged , Pilot Projects , Prospective Studies , United States
2.
J Adolesc Health ; 28(1): 16-25, 2001 Jan.
Article in English | MEDLINE | ID: mdl-11137901

ABSTRACT

PURPOSE: To examine the reliability and validity of the Eating Habits Questionnaire (EHQ) for adolescents and assess eating habits in the context of the Food Pyramid. METHODS: Subjects were 446 students (81.2% female) attending three middle schools (sixth to eighth grades). Over half (56.9%) were African-American. Reliability was assessed with 48-h and 2-week retests on two subsamples (n = 62) and validity was assessed by comparison with three 24-h recalls on an additional subsample (n = 24) and by factor analysis. The EHQ is a self-administered questionnaire consisting of 83 food items and questions assessing food habits and food preparation style. RESULTS: Internal validity, determined with factor analysis, found that 10 factors explained 81.3% of the variance in eating habits. Overall perfect agreement between food groups reported on the 24-h recall and on the EHQ was 56%. Internal consistency, assessed by Cronbach alpha, ranged from .60 to .89. Test-retest correlations were highest at 48 h, ranging from .46 to .85 for the 10 factors. Adolescents ate more servings of fats and sugars (11.2) and meats (6.0) and fewer breads (5.2) and vegetables (1.6) than recommended in Food Pyramid guidelines. In addition, subjects consumed more high-fat protein than low-fat protein servings. CONCLUSIONS: The EHQ is a valid and reliable food frequency questionnaire that has been tested with African-American and white adolescents in the Southeast. It showed that adolescents consume higher than recommended daily servings of fats, sweets, and meats and lower than recommended servings of vegetables and breads.


Subject(s)
Feeding Behavior , Surveys and Questionnaires , Adolescent , Black or African American/statistics & numerical data , Diet Surveys , Factor Analysis, Statistical , Feeding Behavior/ethnology , Female , Humans , Male , North Carolina , Pilot Projects , Psychometrics , Reproducibility of Results , White People/statistics & numerical data
3.
Blood ; 95(12): 3996-4003, 2000 Jun 15.
Article in English | MEDLINE | ID: mdl-10845940

ABSTRACT

T-cell depletion of donor marrow decreases graft-versus-host disease resulting from transplants from unrelated and human leukocyte antigen (HLA)-mismatched related donors. However, there are diverse strategies for T-cell-depleted transplantation, and it is uncertain whether any improve leukemia-free survival (LFS). To compare strategies for T-cell-depleted alternative donor transplants and to compare T-cell depleted with non-T-cell-depleted transplants, we studied 870 patients with leukemia who received T-cell-depleted transplants from unrelated or HLA-mismatched related donors from 1982 to 1994. Outcomes were compared with those of 998 non-T-cell-depleted transplants. We compared LFS using different strategies for T-cell-depleted transplantation considering T-cell depletion technique, intensity of pretransplant conditioning, and posttransplant immune suppression using proportional hazards regression to adjust for other prognostic variables. Five categories of T-cell depletion techniques were considered: narrow-specificity antibodies, broad-specificity antibodies, Campath antibodies, elutriation, and lectins. Strategies resulting in similar LFS were pooled to compare T-cell-depleted with non-T-cell-depleted transplants. Recipients of transplants T-cell depleted by narrow-specificity antibodies had lower treatment failure risk (higher LFS) than recipients of transplants T-cell depleted by other techniques. Compared with non-T-cell-depleted transplants (5-year probability +/- 95% confidence interval [CI] of LFS, 31% +/- 4%), 5-year LFS was 29% +/- 5% (P = NS) after transplants T-cell depleted by narrow-specificity antibodies and 16% +/- 4% (P <.0001) after transplants T-cell depleted by other techniques. After alternative donor transplantation, T-cell depletion of donor marrow by narrow-specificity antibodies resulted in LFS rates that were higher than those for transplants T-cell depleted using other techniques but similar to those for non-T-cell-depleted transplants. (Blood. 2000;95:3996-4003)


Subject(s)
Bone Marrow Transplantation/immunology , HLA Antigens/immunology , Histocompatibility Testing , Leukemia/therapy , Lymphocyte Depletion , T-Lymphocytes/immunology , Tissue Donors , Adolescent , Adult , Antibody Specificity , Bone Marrow Transplantation/mortality , Child , Child, Preschool , Cyclosporine/therapeutic use , Follow-Up Studies , Graft vs Host Disease/prevention & control , Humans , Immunosuppressive Agents/therapeutic use , Infant , Isoantibodies/immunology , Leukemia/immunology , Leukemia/mortality , Middle Aged , Nuclear Family , Registries , Retrospective Studies , Survival Rate , Transplantation, Homologous
4.
Bone Marrow Transplant ; 25(8): 895-8, 2000 Apr.
Article in English | MEDLINE | ID: mdl-10808212

ABSTRACT

Second solid tumors are well known late complications after bone marrow transplantation. Treatment strategies are ill defined. We retrospectively evaluated treatment and outcome in a single institution. From August 1974 to July 1996, six solid tumors were observed in five of 387 patients 2 to 13 years after BMT, corresponding to a probability of developing a second solid tumor of 9% (1-17%, 95 CI) at 15 years: these comprised endometrial carcinoma, carcinoma of the thyroid gland, cervical carcinoma, sarcoma of the small intestine, osteosarcoma of the tibia and ovarian carcinoma. All five patients were treated as intensively as they would be without a history of BMT. At last follow-up four of the five patients were alive and without signs of tumor. We postulate that second solid tumors after BMT should be treated as de novo tumors. Early detection based on consequent clinical follow-up of the transplant patients might explain the relatively good outcome.


Subject(s)
Bone Marrow Transplantation , Neoplasms, Second Primary/therapy , Adenocarcinoma/etiology , Adenocarcinoma/therapy , Adolescent , Adult , Bone Marrow Transplantation/adverse effects , Carcinoma in Situ/etiology , Carcinoma in Situ/therapy , Carcinoma, Papillary/etiology , Carcinoma, Papillary/therapy , Child , Cohort Studies , Combined Modality Therapy , Disease-Free Survival , Fatal Outcome , Female , Humans , Leiomyosarcoma/etiology , Leiomyosarcoma/therapy , Male , Neoplasms, Second Primary/etiology , Osteosarcoma/etiology , Osteosarcoma/therapy , Retrospective Studies , Survival , Transplantation, Homologous , Treatment Outcome
5.
Acta Haematol ; 101(4): 165-72, 1999.
Article in English | MEDLINE | ID: mdl-10436296

ABSTRACT

In a prospective long-term study on the incidence of paroxysmal nocturnal hemoglobinuria (PNH), 115 consecutive patients with severe aplastic anemia (SAA), 97 treated with antilymphocyte globulin (ALG) and 18 with bone marrow transplantation (BMT), were observed over a period of 4-18 years and tested for the presence of complement-sensitive hematopoietic precursor cells with the bone marrow (BM) sucrose test. Sixteen (14%) of the ALG-treated patients developed clinical signs of PNH between 0.5 and 8 years after treatment. Complement-sensitive BM precursors were found in 89% of the SAA patients at some time during their disease, but in none of 18 normal donors. At diagnosis, their proportion was significantly higher in patients who later developed PNH than in patients who later achieved disease-free complete remission (CR). After ALG, the abnormal population was found in both groups, but it was gradually replaced by normal precursors in remission patients. After BMT, the complement-sensitive population decreased to very low numbers in patients with a stable graft, but increased again in 3 patients upon graft rejection. Mimicking the PNH defect by enzymatic removal of glycosyl-phosphatidylinositol (GPI)-linked proteins from CD34+ cells resulted in their complement sensitivity, suggesting that the BM sucrose test identifies precursor cells carrying the PNH defect. In 66 patients, white blood cells (WBC) in peripheral blood (PB) were examined for GPI-deficient populations by flow cytometry (FACS). Ten patients with signs of clinical or laboratory PNH had over 25% complement-sensitive precursor cells in the BM and a GPI-deficient WBC population in the PB. Of 56 SAA patients without PNH, 8 had an abnormal population detectable with both tests, 26 only with the BM sucrose test, 4 only with PB FACS analysis, and in 18, no abnormal cells were detected with either test. In search for parameters which might explain why in some patients the abnormal population expands, while it regresses or disappears in others, we tested the release of IL-2 as a parameter of immune competence. At diagnosis, IL-2 release was approximately 50% of normal in patients who later developed PNH, while it was double the normal value in patients who later achieved CR. We conclude that the majority of SAA patients transiently harbor complement-sensitive precursor cells in the BM. Patients with more than 25% abnormal BM precursors and low endogenous IL-2 release are at risk of progression to clinical PNH.


Subject(s)
Anemia, Aplastic/complications , Complement System Proteins/physiology , Hematopoietic Stem Cells/drug effects , Interleukin-2/physiology , Anemia, Aplastic/drug therapy , Antigens, CD/metabolism , Antilymphocyte Serum/therapeutic use , Bone Marrow Examination , Cells, Cultured , Erythroid Precursor Cells , Flow Cytometry , Hematopoietic Stem Cells/metabolism , Hemoglobinuria, Paroxysmal/epidemiology , Hemoglobinuria, Paroxysmal/etiology , Humans , Interleukin-2/metabolism , Leukocytes/metabolism , Prospective Studies , Sucrose/pharmacology , Time
7.
Schweiz Med Wochenschr ; 128(42): 1611-3, 1998 Oct 17.
Article in German | MEDLINE | ID: mdl-9824893

ABSTRACT

Bone marrow samples used for flow cytometric analysis of plasma cells frequently provide a low plasma cell content. Regularly, samples used for flow cytometry are provided by second step aspiration while the first aspirate is used for cytologic examination. We investigated whether the use of secondary aspirates leads to a systematic underestimation of the bone marrow plasma cell content as a consequence of an increased blood contaminant. To test the hypothesis, plasma cell (CD38bright) percentages were established by flow cytometry in 13 pairs of primary/secondary aspirates. In all cases we found lower plasma cell contents in secondary as compared to primary aspirates (p = 0.0015). Median plasma cell counts in secondary aspirates were 57% lower compared to primary aspirates. We conclude that the use of secondary aspirates leads to systematic underestimation of the bone marrow plasma cell content.


Subject(s)
Bone Marrow/pathology , Flow Cytometry , Plasma Cells/pathology , Cell Count , Humans , Multiple Myeloma/diagnosis , Multiple Myeloma/pathology , Paraproteinemias/diagnosis , Paraproteinemias/pathology , Sensitivity and Specificity
8.
Schweiz Med Wochenschr ; 128(42): 1624-6, 1998 Oct 17.
Article in German | MEDLINE | ID: mdl-9824896

ABSTRACT

The blast crisis in chronic myeloid leukaemia (CML) is morphologically well defined. The aim of this report was to analyze whether immunophenotyping can divide CML blast crises into subtypes as is done in acute de novo leukaemia, and whether a specific CML pattern exists. Between 1991 and 1997 we reevaluated all the immunophenotypes of patients with CML blast crises with special regard to immunological subclassification, expression of CD34, presence of aberrant markers and number of immunological clusters. Twenty-nine CML blast crises were analyzed. Seventeen were myeloid, 11 lymphoid and one biphenotypic. The blast crises were divided into subtypes as de novo acute leukaemias: of the 17 myeloid blast crises 6 were undifferentiated, 5 differentiated and 6 had monocytic differentiation. In the lymphoid blast crises there were no pro-B, 8 common-B and 3 mature-B. No T-lymphoid blast crises were observed. In 26/29 analyses (90%) CD34 was expressed in the blasts. In 17/29 analyses (59%) one or two aberrant markers were found. In summary, immunophenotyping is important in distinguishing between myeloid and lymphoid blast crises. A subclassification, as in acute leukaemias, is possible. We found no specific immunophenotypic CML pattern. A study directly comparing immunophenotyping of CML blast crises with acute de novo leukaemia is planned.


Subject(s)
Blast Crisis/immunology , Immunophenotyping , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/immunology , Adolescent , Adult , Aged , Antigens, CD34/blood , Biomarkers/blood , Blast Crisis/diagnosis , Child , Diagnosis, Differential , Female , Humans , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/classification , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/diagnosis , Male , Middle Aged
9.
Br J Haematol ; 100(2): 393-400, 1998 Feb.
Article in English | MEDLINE | ID: mdl-9488634

ABSTRACT

In a single-centre study the feasibility and efficacy of repeated antilymphocyte globulin (ALG) for patients with severe aplastic anaemia (SAA) not responding to an initial ALG treatment or relapsing after initial response to ALG was evaluated. 139 consecutive patients with newly diagnosed SAA were treated with ALG between 1976 and 1995. 89 patients responded to a first course; 50 patients did not become transfusion independent. Of the 89 responders, 66 remained in remission, 23 relapsed. 43 patients received a second or subsequent course of ALG for failure to respond (n = 25) or relapse (n = 18) and were given a total of 53 courses. Acute reactions in the multiply exposed patients occurred during the first ALG treatment in 11 (26%) and during subsequent exposures in 16/53 courses (30%; P > 0.2). Incidence of serum sickness was 63% (27/43) after the initial course compared to 57% (30/53) after subsequent courses (P > 0.2), but clinical signs of serum sickness occurred earlier after repeated (median 6 d) as compared to initial exposure (13d; P = 0.008). Transfusion-independent haemopoiesis was achieved in 27/43 (63%) and survival probabilities for the 43 patients receiving multiple courses of ALG was 52 +/- 8% at 10 years. The probability of developing a late clonal disorder was 53 +/- 10% after multiple, as compared to 34 +/- 7% after single exposure (P = 0.15). No difference in results was observed between patients retreated for failure to first ALG or for relapse. ALG of the same species can be repeated without increased risks of side-effects in patients with SAA. A second or subsequent course of ALG from the same source can be effective when the first course has failed.


Subject(s)
Anemia, Aplastic/therapy , Antilymphocyte Serum/administration & dosage , Adolescent , Adult , Aged , Antilymphocyte Serum/adverse effects , Child , Child, Preschool , Cohort Studies , Humans , Infant , Middle Aged , Recurrence , Serum Sickness/etiology , Survival Analysis , Treatment Outcome
10.
Br J Haematol ; 99(1): 23-9, 1997 Oct.
Article in English | MEDLINE | ID: mdl-9359497

ABSTRACT

Treatment with busulphan and/or hydroxyurea rarely produces remission in patients with chronic myelogenous leukaemia (CML) in chronic phase. HLA-identical sibling transplants almost always produce remission, and only about 20% of patients relapse post-transplant. The increased anti-leukaemic efficacy of transplants results from intensive pretransplant treatment and immune-mediated anti-leukaemia effects. We studied 433 patients surviving > or = 2 years after diagnosis of CML to determine if patients who have relapsed after a transplant in chronic phase have longer survival from diagnosis than comparable subjects receiving chemotherapy. The chemotherapy cohort included 344 adults < 50 years of age treated on consecutive trials of the Italian Cooperative Study Group on CML between 1973 and 1986. The transplant cohort included 89 patients reported to the International Bone Marrow Transplant Registry who relapsed after an HLA-identical sibling bone marrow transplant carried out between 1978 and 1992. Survivals in the two groups were compared using Cox proportional hazards regression to adjust for prognostic variables. Median survival was 65 months in the chemotherapy cohort and 86 months in the transplant cohort. The 7-year probability (95% confidence interval) of survival was 34% (28-39%) in the chemotherapy cohort and 57% (43-70%) in the transplant cohort (P=0003). There was no difference in survival of patients relapsing after T-cell depleted and non-T-cell-depleted transplants. We conclude that patients who relapse after an HLA-identical sibling bone marrow transplant for CML in chronic phase have longer survival from diagnosis than comparable patients receiving chemotherapy. This effect is most likely to be the result of intensive chemotherapy and/or radiation given for pretransplant conditioning.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Bone Marrow Transplantation , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/therapy , Adolescent , Adult , Cohort Studies , Combined Modality Therapy , Female , Humans , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy , Male , Middle Aged , Recurrence , Risk Factors , Survival Analysis , Survival Rate , Transplantation Conditioning , Treatment Outcome
11.
Bone Marrow Transplant ; 20(7): 607-9, 1997 Oct.
Article in English | MEDLINE | ID: mdl-9337064

ABSTRACT

We observed the occurrence of celiac disease following allogeneic bone marrow transplantation in a patient transplanted for acute leukemia. The marrow donor was his HLA-identical sister, who had suffered from celiac disease since birth. The post-transplant period was characterized by recurrent episodes of diarrhea. Detailed workup showed atrophic intestinal mucosa on histology and anti-gliadin and anti-endomysium antibodies in the serum, features that were not present before transplantation. GVHD was absent at that time. The patient remains free of symptoms on gluten-free diet and slight immunosuppression. This case suggests transmission of celiac disease by bone marrow transplantation and supports the T cell concept in celiac disease.


Subject(s)
Bone Marrow Transplantation/adverse effects , Celiac Disease/etiology , Leukemia/therapy , Acute Disease , Adolescent , Celiac Disease/immunology , Humans , Lymphocyte Depletion , Male , T-Lymphocytes/immunology , Transplantation, Homologous
12.
Blood ; 90(2): 858-64, 1997 Jul 15.
Article in English | MEDLINE | ID: mdl-9226187

ABSTRACT

Bone marrow transplants for severe aplastic anemia were first performed in the 1970s. Transplant regimens, supportive care, and patient selection have changed substantially since then. Our objective was to determine the impact of these changes on transplant outcome. We studied 1,305 recipients of HLA-identical sibling transplants for aplastic anemia between 1976 and 1992, reported to the IBMTR by 179 centers. We compared survival of transplants performed in three intervals (1976 through 1980 [n = 186], 1981 through 1987 [n = 648], and 1988 through 1992 [n = 471]) using Cox proportional hazards regression. Five-year survival (+/-95% confidence interval) increased from 48% +/- 7% in the 1976-1980 cohort to 66% +/- 6% in the 1988-1992 cohort (P < .0001). Risks of graft-versus-host disease (GVHD) and interstitial pneumonia decreased over time, but the risk of graft failure did not. Higher long-term survival resulted primarily from decreased mortality in the first 3 months posttransplantation. Late mortality risks were low and changed little over the intervals studied. In multivariate analysis, changes in transplantation strategies accounted for most but not all of the improved outcome. Use of cyclosporine to prevent GVHD was the most important factor. Changes in patient selection did not seem to explain improved survival. Survival after HLA-identical sibling bone marrow transplantations for aplastic anemia has improved since 1976. Changes in GVHD prophylaxis account for much of this improvement. Other changes may also operate.


Subject(s)
Anemia, Aplastic/therapy , Bone Marrow Transplantation , Treatment Outcome , Age Factors , Anemia, Aplastic/mortality , Bone Marrow Transplantation/mortality , Bone Marrow Transplantation/physiology , Cohort Studies , Confidence Intervals , Female , Graft Survival , Graft vs Host Disease/epidemiology , Histocompatibility Testing , Humans , Immunosuppression Therapy/methods , Lung Diseases, Interstitial/epidemiology , Male , Multivariate Analysis , Proportional Hazards Models , Retrospective Studies , Risk Factors , Survival Rate , Treatment Failure
13.
Ann Hematol ; 75(5-6): 239-41, 1997.
Article in English | MEDLINE | ID: mdl-9433383

ABSTRACT

Of 229 consecutive patients receiving allogeneic blood or bone marrow stem cell transplants for acute myeloid leukemia, chronic myeloid leukemia, or myelodysplastic syndrome between 1974 and 1996, 52 patients relapsed. The original tumor recurred as granulocytic sarcoma (chloroma) in three patients (1.3%). Chloroma was found in the ovary in two patients and in the central nervous system in one patient. None of these three patients had experienced > or = grade II acute or more than limited chronic graft-versus-host disease. The intervals between transplantation and recurrence with chloroma were 2, 6, and 13 years. Two patients received a second transplant, and all three died of treatment sequelae.


Subject(s)
Bone Marrow Transplantation , Leukemia, Myeloid/etiology , Leukemia, Myeloid/pathology , Myelodysplastic Syndromes/pathology , Adult , Female , Humans , Leukemia, Myeloid/therapy , Male , Middle Aged , Myelodysplastic Syndromes/therapy , Sarcoma/etiology , Sarcoma/pathology , Transplantation, Homologous
14.
Blood ; 88(12): 4493-9, 1996 Dec 15.
Article in English | MEDLINE | ID: mdl-8977241

ABSTRACT

Flt3 ligand (flt3L) is a member of a small family of cytokines acting as tyrosine kinase receptor ligands that stimulate the proliferation of primitive hematopoietic progenitors in vitro. To gain insight into the physiological role of flt3L in early hematopoiesis, levels of flt3L were determined in serum of patients with multilineage bone marrow failure and related to the severity of stem cell depletion. In patients with aplastic anemia (AA) and in cancer patients with chemotherapy-induced transient suppression of hematopoiesis, flt3L fluctuated in an inverse relationship to the degree of bone marrow failure. In severe AA at diagnosis, levels of circulating soluble flt3L were highly elevated (2,653 +/- 353 pg/mL) as compared with normal blood serum values of 14 +/- 39 pg/mL. Flt3L returned to near normal levels within the first 3 months following successful bone marrow transplantation and in autologous remission induced by immunosuppressive therapy with antilymphocyte globulin (ALG; 100 +/- 31 and 183 +/- 14 pg/mL, respectively). In contrast, rejection of the graft or relapse of the disease after ALG was accompanied by an increase to high pretreatment concentrations of the circulating cytokine (3,770 +/- 2,485 and 1,788 +/- 233 pg/mL, respectively). Flt3L in serum inversely correlated with the colony-forming ability of AA bone marrow precursors in vitro (R = -.86), indicating that the concentration of the ligand reflects hematopoiesis at the progenitor cell level. Flt3L increased to 2,500 pg/mL in the serum of leukemia patients during chemoradiotherapy-induced bone marrow suppression and returned to normal values along with hematopoietic recovery. Expression of the membrane-bound form of flt3L was significantly elevated in mononuclear bone marrow and peripheral blood cells from patients with severe pancytopenia, suggesting de novo synthesis of the factor in response to bone marrow failure. The data provide a strong argument for the involvement of flt3L in the regulation of early hematopoiesis in vivo.


Subject(s)
Anemia, Aplastic/physiopathology , Bone Marrow/abnormalities , Hematopoietic Stem Cells/physiology , Proto-Oncogene Proteins/metabolism , Receptor Protein-Tyrosine Kinases/metabolism , Anemia, Aplastic/blood , Anemia, Aplastic/drug therapy , Bone Marrow Diseases/chemically induced , Drug-Related Side Effects and Adverse Reactions , Hematopoiesis/drug effects , Hematopoiesis/physiology , Humans , Leukemia/blood , Leukemia/drug therapy , Leukemia/radiotherapy , Proto-Oncogene Proteins/blood , Receptor Protein-Tyrosine Kinases/blood , Receptors, Cell Surface , Stem Cell Factor , fms-Like Tyrosine Kinase 3
15.
Schweiz Med Wochenschr ; 126(45): 1944-5, 1996 Nov 09.
Article in German | MEDLINE | ID: mdl-8946598

ABSTRACT

In acute promyelocytic leukemia (APL), disseminated intravascular coagulation is frequently observed. Massive alveolar bleeding can lead to respiratory insufficiency, requiring tracheal intubation and mechanical ventilation. Today all-transretinoic acid (ATRA) is part of induction chemotherapy in acute promyelocytic leukemia. The administration of ATRA is oral. No intravenously administered form is available. ATRA can be administered to intubated patients in the following manner: the daily amount of ATRA is placed in a sterile 50 ml tube. After addition of about 20 ml of sterile water the tube is heated in a waterbath to a temperature of 37 degrees C until the capsules melt and the suspension is completely liquid. The resulting oily fluid is then administered via nasogastric tube. We have treated 2 patients with acute promyelocytic leukemia intubated due to massive alveolar bleeding in this manner, and have observed a differentiation of promyelocytes to granulocytes and complete remission in both patients, indicating that the ATRA administered had been resorbed intestinally.


Subject(s)
Antineoplastic Agents/therapeutic use , Leukemia, Promyelocytic, Acute/drug therapy , Tretinoin/therapeutic use , Adolescent , Adult , Female , Humans , Male , Remission Induction , Treatment Outcome
16.
Leukemia ; 10(11): 1687-91, 1996 Nov.
Article in English | MEDLINE | ID: mdl-8892667

ABSTRACT

There is controversy whether adults with acute myelogenous leukemia (AML) in first remission are best treated with chemotherapy or an HLA-identical sibling bone marrow transplant. We studied 1097 adults, 16-50 years old, with AML in first remission. Results of transplants from HLA-identical siblings reported to the International Bone Marrow Transplant Registry (IBMTR; n = 901) were compared with results of chemotherapy in comparable persons treated by the German AML Cooperative Group (GAMLCG; n = 196). Preliminary analyses identified subject- and disease-related variables differing between the cohorts and associated with treatment outcome within each cohort. We adjusted for these variables and differences in time-to-treatment in subsequent comparisons of treatment-related mortality, relapse, survival and leukemia-free survival (LFS). Five-year probability of treatment-related mortality was greater for transplants than chemotherapy (43% (95% confidence interval, 37-49%) vs 7% (3-11%); P< 0.0001). Five-year relapse probability was less for transplants than chemotherapy (24% (20-28%) vs 63% (55-71%); P< 0.0001). Five-year probability of survival was similar with transplants and chemotherapy (48% (43-53%) vs 42% (33-51%); P = 0.24). Five-year LFS probability was higher for transplants than chemotherapy (46% (42-50%) vs 35% (28-41%); P= 0.01). These data indicate that bone marrow transplants from HLA-identical siblings result in comparable survival but greater LFS than chemotherapy in adults with AML in first remission.


Subject(s)
Bone Marrow Transplantation/immunology , HLA Antigens/immunology , Leukemia, Myeloid, Acute/therapy , Adolescent , Adult , Cohort Studies , Female , Histocompatibility Testing , Humans , Leukemia, Myeloid, Acute/immunology , Male , Middle Aged , Nuclear Family , Treatment Outcome
17.
Ann Intern Med ; 125(10): 799-806, 1996 Nov 15.
Article in English | MEDLINE | ID: mdl-8928986

ABSTRACT

BACKGROUND: Invasive mycoses are an important cause of illness and death in immunocompromised patients. Infections with molds other than aspergilli have been increasingly seen in patients with hematologic cancers, but epidemics of these infections have not yet been reported. OBJECTIVE: To describe an outbreak of invasive mycoses with Paecilomyces lilacinus in severely neutropenic patients. DESIGN: An outbreak investigation. SETTING: The hematology-oncology isolation and bone marrow transplantation unit of the University Hospital, Basel, Switzerland. PATIENTS: 25 consecutive patients admitted between 17 August 1993 (the date of the first manifestation of P. lilacinus infection) and 31 October 1993 (when the unit was closed). MEASUREMENTS: Clinical and microbiological data, including histologic findings; cultures from several patient sites; and environmental examinations of potential airborne, parenteral, enteric, and horizontal routes of transmission. Infections were defined by the isolation of P. lilacinus from clinically evident skin eruptions. RESULTS: 12 of the 25 patients (48%) were infected or colonized. Nine patients (36%), including all bone marrow transplant recipients, had documented invasive P. lilacinus infections. All 9 infected patients had papular, pustular, or necrotic skin eruptions. Two patients with severe graft-versus-host disease died with refractory fungal disease; 1 also had microbiologically documented endophthalmitis and kidney infiltrates. Seven affected patients no longer had P. lilacinus after recovery of bone marrow function. The organism was resistant in vitro to amphotericin B, itraconazole, and fluconazole. Patients did not respond clinically to these agents. The outbreak was ultimately traced to a contaminated, commercially available, pharmaceutically prepared skin lotion. The outbreak ended after the skin lotion was recalled and has not recurred after a follow-up period of 2 years. CONCLUSION: Contaminated skin lotion is a potential cause of opportunistic fungal infections in immunocompromised hosts. Paecilomyces lilacinus is a common saprophytic mold that can cause, by direct cutaneous inoculation, invasive infections associated with illness and death.


Subject(s)
Cross Infection/epidemiology , Disease Outbreaks , Mycoses/epidemiology , Opportunistic Infections/epidemiology , Paecilomyces , Adolescent , Adult , Aged , Bone Marrow Transplantation/immunology , Case-Control Studies , Cross Infection/transmission , Dermatomycoses/epidemiology , Dermatomycoses/transmission , Female , Humans , Immunocompromised Host , Male , Middle Aged , Mycoses/transmission , Neoplasms/immunology , Neutropenia/immunology , Ointments , Opportunistic Infections/transmission , Switzerland/epidemiology
18.
Schweiz Med Wochenschr ; 126(43): 1834-41, 1996 Oct 26.
Article in German | MEDLINE | ID: mdl-9005523

ABSTRACT

We present 5 cases with thrombocytopenia and abnormal platelet function. The diagnosis of Bernard-Soulier syndrome was suspected in some subjects of advanced age on the ground of morphologic changes in the thrombocytes and of low platelet counts with or without prolonged bleeding time. The platelets showed normal aggregation with adrenalin, ADP and collagen but abnormal agglutination with ristocetine. All patients had normal von Willebrand factor levels in plasma. Flow cytometry demonstrated on thrombocytes lack of GP Ib expression of varying degree in comparison to normal controls, using various anti-GP Ib-antibodies (CD42b). The combination of these findings confirmed the diagnosis of Bernard-Soulier syndrome with varying expression of GP Ib. Flow cytometry and the use of specific monoclonal antibodies may be a rapid and reliable diagnostic tool. Differential diagnosis and treatment strategies are discussed. A congenital thrombopathy should always be considered in patients with thrombocytopenia of unknown origin and abnormal platelet morphology.


Subject(s)
Bernard-Soulier Syndrome/complications , Thrombocytopenia/etiology , Adult , Aged , Aged, 80 and over , Bernard-Soulier Syndrome/blood , Bernard-Soulier Syndrome/etiology , Bleeding Time , Blood Platelets/chemistry , Female , Flow Cytometry , Glycoproteins/blood , Humans , Immunophenotyping , Male , Platelet Aggregation , Platelet Count , Thrombocytopenia/blood
19.
Ann Hematol ; 73(3): 149-51, 1996 Sep.
Article in English | MEDLINE | ID: mdl-8841105

ABSTRACT

Optimum treatment of severe neutropenia, a major factor for morbidity and mortality in T-large granular lymphocyte (LGL) leukemia, is undefined. We observed a rapid improvement of the neutrophil count in a patient with T-LGL leukemia and severe neutropenia after the combined administration of antilymphocyte-globulin (ALG), cyclosporin A, prednisone, and granulocyte colony-stimulating factor (G-CSF). Although G-CSF treatment was terminated after 7 days, the neutrophil count has persisted above 1.0 x 10(9)/1 for up to 6 months now. Oral methotrexate is given continuously as treatment for T-LGL leukemia. The response to this immunosuppressive regimen suggests a T-cell-mediated mechanism as the underlying cause for neutropenia in T-LGL leukemia.


Subject(s)
Immunosuppression Therapy , Leukemia, Lymphoid/therapy , Leukemia, T-Cell/therapy , Neutropenia/therapy , Humans , Leukocyte Count , Male , Middle Aged , Neutropenia/pathology , Neutrophils/pathology
20.
J Sch Health ; 66(3): 106-11, 1996 Mar.
Article in English | MEDLINE | ID: mdl-8857159

ABSTRACT

The Youth Health Survey (YHS) was developed as part of a school-based longitudinal study (Cardiovascular Health in Children and Youth) to assess and track behavior and attitudes related to cardiovascular risk factors in children and adolescents. This paper reports the psychometric properties of each of the subscales of the YHS and the results of a pilot study with sixth, seventh and eighth grade students (n = 205) at two schools in the Southeast. The eight subscales of the YHS assess health habits and attitudes of the adolescent as well as selected peer and family influences on those health behaviors. Internal consistencies for seven of the eight subscales ranged from .74 to .89. Test-retest reliability for six of the eight subscales ranged from .67 to .89. Construct validity was established through factor analyses of four of six of the subscales. Findings support using the YHS with some minor revisions to assess behaviors, attitudes and influences which may lead to CVD in adulthood.


Subject(s)
Cardiovascular Diseases/prevention & control , Health Behavior , Health Status Indicators , Adolescent , Analysis of Variance , Attitude to Health , Family , Female , Humans , Male , North Carolina , Peer Group , Reproducibility of Results , Risk Factors , Surveys and Questionnaires
SELECTION OF CITATIONS
SEARCH DETAIL
...